Cargando…
Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil
BACKGROUND: Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared. METHODS: In a double-blinded crossover tria...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168413/ https://www.ncbi.nlm.nih.gov/pubmed/21854650 http://dx.doi.org/10.1186/1476-511X-10-145 |
_version_ | 1782211386403717120 |
---|---|
author | Schuchardt, Jan Philipp Schneider, Inga Meyer, Henrike Neubronner, Juliane von Schacky, Clemens Hahn, Andreas |
author_facet | Schuchardt, Jan Philipp Schneider, Inga Meyer, Henrike Neubronner, Juliane von Schacky, Clemens Hahn, Andreas |
author_sort | Schuchardt, Jan Philipp |
collection | PubMed |
description | BACKGROUND: Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared. METHODS: In a double-blinded crossover trial, we compared the uptake of three EPA+DHA formulations derived from fish oil (re-esterified triacylglycerides [rTAG], ethyl-esters [EE]) and krill oil (mainly PL). Changes of the FA compositions in plasma PL were used as a proxy for bioavailability. Twelve healthy young men (mean age 31 y) were randomized to 1680 mg EPA+DHA given either as rTAG, EE or krill oil. FA levels in plasma PL were analyzed pre-dose and 2, 4, 6, 8, 24, 48, and 72 h after capsule ingestion. Additionally, the proportion of free EPA and DHA in the applied supplements was analyzed. RESULTS: The highest incorporation of EPA+DHA into plasma PL was provoked by krill oil (mean AUC(0-72 h): 80.03 ± 34.71%*h), followed by fish oil rTAG (mean AUC(0-72 h): 59.78 ± 36.75%*h) and EE (mean AUC(0-72 h): 47.53 ± 38.42%*h). Due to high standard deviation values, there were no significant differences for DHA and the sum of EPA+DHA levels between the three treatments. However, a trend (p = 0.057) was observed for the differences in EPA bioavailability. Statistical pair-wise group comparison's revealed a trend (p = 0.086) between rTAG and krill oil. FA analysis of the supplements showed that the krill oil sample contained 22% of the total EPA amount as free EPA and 21% of the total DHA amount as free DHA, while the two fish oil samples did not contain any free FA. CONCLUSION: Further studies with a larger sample size carried out over a longer period are needed to substantiate our findings and to determine differences in EPA+DHA bioavailability between three common chemical forms of LC n-3 FA (rTAG, EE and krill oil). The unexpected high content of free EPA and DHA in krill oil, which might have a significant influence on the availability of EPA+DHA from krill oil, should be investigated in more depth and taken into consideration in future trials. |
format | Online Article Text |
id | pubmed-3168413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31684132011-09-08 Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil Schuchardt, Jan Philipp Schneider, Inga Meyer, Henrike Neubronner, Juliane von Schacky, Clemens Hahn, Andreas Lipids Health Dis Research BACKGROUND: Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared. METHODS: In a double-blinded crossover trial, we compared the uptake of three EPA+DHA formulations derived from fish oil (re-esterified triacylglycerides [rTAG], ethyl-esters [EE]) and krill oil (mainly PL). Changes of the FA compositions in plasma PL were used as a proxy for bioavailability. Twelve healthy young men (mean age 31 y) were randomized to 1680 mg EPA+DHA given either as rTAG, EE or krill oil. FA levels in plasma PL were analyzed pre-dose and 2, 4, 6, 8, 24, 48, and 72 h after capsule ingestion. Additionally, the proportion of free EPA and DHA in the applied supplements was analyzed. RESULTS: The highest incorporation of EPA+DHA into plasma PL was provoked by krill oil (mean AUC(0-72 h): 80.03 ± 34.71%*h), followed by fish oil rTAG (mean AUC(0-72 h): 59.78 ± 36.75%*h) and EE (mean AUC(0-72 h): 47.53 ± 38.42%*h). Due to high standard deviation values, there were no significant differences for DHA and the sum of EPA+DHA levels between the three treatments. However, a trend (p = 0.057) was observed for the differences in EPA bioavailability. Statistical pair-wise group comparison's revealed a trend (p = 0.086) between rTAG and krill oil. FA analysis of the supplements showed that the krill oil sample contained 22% of the total EPA amount as free EPA and 21% of the total DHA amount as free DHA, while the two fish oil samples did not contain any free FA. CONCLUSION: Further studies with a larger sample size carried out over a longer period are needed to substantiate our findings and to determine differences in EPA+DHA bioavailability between three common chemical forms of LC n-3 FA (rTAG, EE and krill oil). The unexpected high content of free EPA and DHA in krill oil, which might have a significant influence on the availability of EPA+DHA from krill oil, should be investigated in more depth and taken into consideration in future trials. BioMed Central 2011-08-22 /pmc/articles/PMC3168413/ /pubmed/21854650 http://dx.doi.org/10.1186/1476-511X-10-145 Text en Copyright ©2011 Schuchardt et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Schuchardt, Jan Philipp Schneider, Inga Meyer, Henrike Neubronner, Juliane von Schacky, Clemens Hahn, Andreas Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil |
title | Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil |
title_full | Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil |
title_fullStr | Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil |
title_full_unstemmed | Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil |
title_short | Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil |
title_sort | incorporation of epa and dha into plasma phospholipids in response to different omega-3 fatty acid formulations - a comparative bioavailability study of fish oil vs. krill oil |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3168413/ https://www.ncbi.nlm.nih.gov/pubmed/21854650 http://dx.doi.org/10.1186/1476-511X-10-145 |
work_keys_str_mv | AT schuchardtjanphilipp incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil AT schneideringa incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil AT meyerhenrike incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil AT neubronnerjuliane incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil AT vonschackyclemens incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil AT hahnandreas incorporationofepaanddhaintoplasmaphospholipidsinresponsetodifferentomega3fattyacidformulationsacomparativebioavailabilitystudyoffishoilvskrilloil |